NewsBenzingaSarepta Therapeutics Presents New Data At 31st Annual Congress Of WMS That Provide Evidence Of Clinically Meaningful Functional Benefit Of ELEVIDYS In Older Ambulatory Patients With Duchenne Muscular Dystrophy Sarepta Therapeutics Presents New Data At 31st Annual Congress Of WMS That Provide Evidence Of Clinically Meaningful Functional Benefit Of ELEVIDYS In Older Ambulatory Patients With Duchenne Muscular Dystrophy Benzinga 2026.09.30 12:38 (GMT+0) Open on Benzinga Other news Nasdaq Tumbles Over 2%, Records Weekly Loss: Investor Sentiment Weakens, Fear & Greed Index Moves to ‘Extreme Fear’ Zone Fifth Third Bancorp, Cleveland-Cliffs and 3 Stocks to Watch Heading Into Monday Exelon: Shelter From The Storm And Nice Yield As Utilities Catch A Bid (NASDAQ:EXC) SpaceX Launch Could Create a Giant ‘Jellyfish’ in the Sky Over the East Coast Monday Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW NVIDIA GTC Berlin kicks off October 20, Jensen Huang to deliver keynote on October 21
Nasdaq Tumbles Over 2%, Records Weekly Loss: Investor Sentiment Weakens, Fear & Greed Index Moves to ‘Extreme Fear’ Zone
Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW
